Answers are grounded in this paper and cite their sources.
Background Gynaecological cancers are an important public health concern, yet evidence on their epidemiological patterns and temporal trends in Sri Lanka remains limited. This study evaluated trends in incidence and mortality and characterised histological patterns across gynaecological cancer sites. Methods This population-based study used Sri Lanka cancer registry data and national mortality data for 2005–2022. Age-standardised incidence (ASIR) and mortality (ASMR) rates were calculated using the World Health Organization world standard population. Joinpoint regression was used to estimate annual and average annual percent changes (APC/AAPC) with 95% confidence intervals. Histological distribution was assessed for the major cancer sites. Results A total of 48,603 gynaecological cancer cases were recorded, led by cervical (n = 18,013), ovarian (n = 15,765), and uterine (n = 12,766) cancers. Overall ASIR increased from 18.62 to 29.95 per 100,000, with an AAPC of 3.25% (95% CI: 2.30–4.41; p < 0.001). Uterine cancer showed the steepest increase (AAPC 8.21%; 95% CI: 7.01, 10.04; p < 0.001), followed by ovarian cancer, whereas cervical cancer incidence remained stable (p = 0.53). Vulval, vaginal, and other unspecified female genital cancers also showed significant increases in age-standardised incidence. Uterine cancer accounted for the highest number of deaths (n = 4,115) with a non-significant decline (AAPC − 0.80%). Cumulative risk increased most markedly for corpus uteri cancer, with significant trends in both age groups, and for vaginal cancer among women aged 0–74 years. Histology was predominantly squamous cell carcinoma for cervical cancer (77.8%), while adenomas and adenocarcinomas predominated in uterine corpus cancer (73.1%). Cystic, mucinous, and serous neoplasms were the most common ovarian histological group (44.1%). Conclusion Sri Lanka's gynaecological cancer burden is shifting, with a growing contribution from uterine and ovarian cancers alongside a persistent cervical cancer burden, in the context of demographic and metabolic transitions. These findings support strengthening organised cervical cancer screening and sustained human papillomavirus vaccination while expanding diagnostic and treatment capacity for uterine and ovarian cancers.
No takes yet. Share an insight, caveat, or question.
Weerasooriya et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: